U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07609914) titled 'A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine' on May 20.
Brief Summary: Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack.
The primary purpose of this study is to evaluate the s...